Abstract
The p75 neurotrophin receptor (p75NTR) is a single membrane-spanning receptor in the tumor necrosis factor (TNF) death domain containing receptor family. p75NTR has multiple faces of biological or pathogenic functions by partnering with the three major neurotrophin receptors, including tropomyosin receptor kinase (Trk), sortilin and Nogo receptors. By partnering with different co-receptors, p75NTR regulates the binding of mature or pro-neurotrophins and activation of different signaling pathways, resulting in outcomes ranging from growth and survival to cell death or apoptosis. In this review, we summarized the role of p75NTR in maintaining the hemostasis of the brain, and briefly introduced its participation in the pathogenesis of several neurodegenerative diseases. The complexity of p75NTR enables it to be a potent therapeutic target of many diseases by modulating functions of the receptor.
Keywords: p75 neurotrophin receptor, sortilin, apoptosis, neurogensis, brain.
Current Alzheimer Research
Title:Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Volume: 14 Issue: 5
Author(s): Changyue Gao*, Lili Zhang, Dayu Sun, Jingcheng Li, Xiuqing Yao, Huadong Zhou and Yanjiang Wang
Affiliation:
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, 10 Changjiang Branch Road, Yuzhong District, Chongqing,China
Keywords: p75 neurotrophin receptor, sortilin, apoptosis, neurogensis, brain.
Abstract: The p75 neurotrophin receptor (p75NTR) is a single membrane-spanning receptor in the tumor necrosis factor (TNF) death domain containing receptor family. p75NTR has multiple faces of biological or pathogenic functions by partnering with the three major neurotrophin receptors, including tropomyosin receptor kinase (Trk), sortilin and Nogo receptors. By partnering with different co-receptors, p75NTR regulates the binding of mature or pro-neurotrophins and activation of different signaling pathways, resulting in outcomes ranging from growth and survival to cell death or apoptosis. In this review, we summarized the role of p75NTR in maintaining the hemostasis of the brain, and briefly introduced its participation in the pathogenesis of several neurodegenerative diseases. The complexity of p75NTR enables it to be a potent therapeutic target of many diseases by modulating functions of the receptor.
Export Options
About this article
Cite this article as:
Gao Changyue*, Zhang Lili, Sun Dayu, Li Jingcheng, Yao Xiuqing, Zhou Huadong and Wang Yanjiang, Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies, Current Alzheimer Research 2017; 14 (5) . https://dx.doi.org/10.2174/1567205014666170110142415
DOI https://dx.doi.org/10.2174/1567205014666170110142415 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound
Current Pharmaceutical Design Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Structure-Based Design of Benzimidazole Sugar Conjugates: Synthesis, SAR and In Vivo Anti-inflammatory and Analgesic Activities
Medicinal Chemistry Second Generation Adeno-Associated Virus Type 2-based Gene Therapy Systems with the Potential for Preferential Integration into AAVS1
Current Gene Therapy Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase
Current Computer-Aided Drug Design In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Current Inhibitors of Checkpoint Kinase 2
Current Medicinal Chemistry